key: cord-0890697-68tjyb2f
authors: Bussiere, N.; Mei, J.; Levesque-Boissonneault, C.; Blais, M.; Carazo, S.; Gros-Louis, F.; Laforce, R.; DeSerres, G.; Dupre, N.; Frasnelli, J.
title: Persisting Chemosensory Impairments in 366 Healthcare Workers Following COVID-19: An 11-Month Follow-up.
date: 2021-12-27
journal: nan
DOI: 10.1101/2021.12.20.21268066
sha: 591d7ae88f53b30dc8be9a26f9e8df1a6c3578b4
doc_id: 890697
cord_uid: 68tjyb2f

Background and Objectives: Olfactory and gustatory dysfunctions (OD, GD) are prevalent symptoms following COVID-19 and persist in 6%-44% of individuals in the first months after the infection. As only few reports have described their prognosis more than 6 months later, the main objective of this study was to assess the prevalence of OD and GD 11 months after COVID-19. We also aimed to determine test-retest reliability of subjective chemosensory ratings for the follow-up of chemosensory sensitivity, as this measure is often used for remote follow-up. Methods: Inclusion criteria included a PCR-confirmed SARS-CoV-2 infection; exclusion criteria were the presence of other respiratory infections and chronic sinusitis. To assess whether OD and GD had changed compared to pre-pandemic levels, we designed an observational study and distributed an online questionnaire assessing quantitative chemosensory function to healthcare workers 5 and 11 months after COVID-19. Specifically, we assessed olfaction, gustation, and trigeminal sensitivity (10-point visual analog scale) and function (4-point Likert scale) separately. We further assessed clinically relevant OD using the Chemosensory Perception Test, a psychophysical test designed to provide a reliable remote olfactory evaluation. Qualitative chemosensory dysfunction was also assessed. Results: We included a total of 366 participants (mean age of 44.8 years old (SD: 11.7)). They completed the last online questionnaire 10.6 months (SD: 0.7) after the onset of COVID-19 symptoms. Of all participants, 307 (83.9%) and 301 (82.2%) individuals retrospectively reported lower olfactory or gustatory sensitivity during the acute phase of COVID-19. Eleven months later, 184 (50.3%) and 163 (44.5%) indicated reduced chemosensory sensitivity, 32.2% reported impairment of olfactory function while 24.9% exhibited clinically relevant OD. Three variables predicted OD at follow-up, namely chest pain and GD during COVID-19 and presence of phantosmia at 5 months. Olfactory sensitivity ratings had a high test-retest reliability (intraclass correlation coefficient: 0.818 (95% CI: 0.760 - 0.860)) Discussion: This study suggests that chemosensory dysfunctions persist in a third of COVID-19 patients 11 months after COVID-19. Subjective measures have a high test-retest reliability and thus can be used to monitor post-COVID-19 OD. OD appears to be a common long-term symptom of COVID-19 important to consider when treating patients.

The COVID-19 pandemic has been ongoing for over two years, and many advances have been made to further understand its pathogenesis and treatment. The high rate of post-COVID-19 olfactory dysfunction (OD) has brought interest to the field of post-viral OD, yet many questions remain unanswered regarding the duration and pathophysiology of this symptom 1 . Even before the pandemic, viral infections of the upper respiratory tract (URTI) were known to be a major cause of OD 2 . For patients with persisting OD, impairment may be quantitative (e.g., anosmia, hyposmia) and/or qualitative (e.g., parosmia, phantosmia) 3 . Both forms of OD may significantly decrease quality of life (QoL), and this impact gets worse as OD persists 4 .

Initial presentation of COVID-19-induced OD is now well described: sudden loss affecting 50% to 75% of infected individuals 5 . For most individuals, quantitative OD is predominant, but some have reported parosmia (altered perception of real stimuli) and/or phantosmia (perception of odor in absence of stimuli) in the acute phase 6, 7 . Some individuals also present with other chemosensory alterations, such as gustatory dysfunction (GD; altered ability to taste sweet, sour, salty, bitter or umami) or trigeminal dysfunction (TD; altered ability to perceive spiciness, freshness, carbonation) [8] [9] [10] . Although most patients do recover within weeks from these dysfunctions, many remain symptomatic and their condition evolves into long-haul COVID-19 11, 12 . Six months after onset of symptoms, 5% to 60% of patients suffer from persistent OD and 10 to 35% have persistent GD [13] [14] [15] . Few studies reported prevalence of TD, although a recent study which used psychophysical tests found a correlation between OD and TD at 6 months following a confirmed SARS-CoV-2 infection 16 . This study could not establish a prevalence of trigeminal dysfunction due to their testing methods. Moreover, prevalence of parosmia increases with time in COVID-19 patients, which is in line with the theory that qualitative dysfunctions following viral . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 27, 2021. ; https://doi.org/10.1101/2021.12.20.21268066 doi: medRxiv preprint infection could result from faulty regeneration of olfactory sensory neurons [17] [18] [19] . Although many patients with long-haul COVID-19 have persistent OD, very few studies describe the prognosis for such individuals past 6-months after symptom onset.

As described in a previous report, 52%, 42% and 23% of a cohort of healthcare workers with mild COVID-19 experienced OD, GD, and TD respectively at 5 months after onset of COVID-19 20 . For other viruses, recovery of postviral OD can be expected in up to 80% one year following onset of infection 21 . Therefore, long-term follow-up of patients is necessary to further understand the evolution of post-COVID-19 OD and eventually offer resources for clinicians and patients alike.

We followed up the same cohort of healthcare workers with a PCR confirmed SARS-CoV-2 infection between 12 February and 11 June 2020, who consented to fill an online questionnaire and to self-report measurements from the Chemosensory Perception Test (CPT), a novel and easy to use olfactory test. Data for the 5-month follow-up questionnaire from this cohort is published 20 .

This present manuscript therefore compares data obtained at 5 and 11 months collected from the same cohort 20 .

We had three specific objectives for this study: first, we aimed to determine the percentage of individuals who experience OD, GD, or TD 11 months after COVID-19. To do so, we used three different approaches to grasp different aspects of chemosensory dysfunction. Specifically, we assessed (a) the proportion of participants who indicated chemosensory sensitivity below levels prior to the infection (persistent reduction of chemosensory sensitivity); (b) the proportion of participants who indicated chemosensory function was much or a bit worse than before the infection (impairment of chemosensory function); (c) the proportion of participants who had a result indicative of dysfunction in a semi-objective test (clinically relevant OD). Second, we aimed 6 at identifying the factors that best predict olfactory dysfunction 11 months after COVID-19. Third, we aimed to determine the test-retest reliability of subjective chemosensory ratings.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint 

Standard protocol approvals, registrations, and patient consents This study was reviewed and approved by the research ethics board of the CHU de Québec -Université Laval (MP-20-2021-5228) and all protocols were reviewed by an independent Scientific Review Committee. All participants provided an online informed consent prior to participation. The study received funding from the Fonds de recherche du Québec-Santé (FRQS).

No compensation or incentive was offered to participants.

Healthcare workers with a positive SARS-CoV-2 PCR test were recruited among those who had completed the initial online questionnaire at 5 months after onset of symptoms. Inclusion criteria were (1) completed the follow-up online questionnaire (2) did not report other respiratory diseases (bacterial or viral infection) within 2 weeks prior to questionnaire completion, chronic sinusitis, or traumatic brain injury, and (3) did not have a symptomatic SARS-CoV-2 reinfection (Figure 1 ).

Data were collected from March 1 to April 27, 2021. Up to four attempts were made via email to reach and recruit potential participants.

Online questionnaire All participants were invited to complete an online questionnaire as introduced earlier 20 . The questionnaire comprised items on chemosensory self-assessment including demographic data, changes to medical history (based on the follow-up questionnaire of the Global Consortium on Chemosensory Research 8, 22 ). Finally, we remotely administered the CPT, a semi-objective test for chemosensory function 20 (eAppendix 1).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. ability to be lower than their self-evaluation at baseline (at T0; i.e.: T3 < T0), they were classified as exhibiting (a) persistent reduction of chemosensory sensitivity. In addition, these data also allowed us to compare scores from one timepoint to another (i.e.: T0 vs T2 vs T3).

Participants were then asked to compare their current (at T3) chemosensory function with those prior to the SARS-CoV-2 infection (T0), for which they may choose one of the following statements: (1) much worse, (2) a bit worse, (3) the same, (4) a bit better, and (5) much better.

Participants from categories (1) and (2) were classified as exhibiting (b) impairment of chemosensory function. For participants with self-reported OD (GD), we also collected information about the presence of current parosmia/phantosmia (alterations in the 5 taste qualities, i.e., sweet, salty, sour, bitter, umami).

Finally, we remotely administered the CPT. This olfactory test requires participants to smell specific household substances (peanut butter, jam, coffee) and report the perceived intensity of . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 27, 2021. ; https://doi.org/10.1101/2021.12.20.21268066 doi: medRxiv preprint each on a 10-point VAS 20 . Scores were obtained by calculating the mean score reported for the 3 substances. Based on earlier data, we classified participants with a score lower or equal to 7 as exhibiting (c) clinically relevant OD 20 .

A custom Python script (Python 3.7.5, Python Software Foundation, https://www.python.org) and To determine differentiating characteristics between patients with and without impairment of chemosensory function at T3 after COVID-19 among those with reduction of chemosensory sensitivity during COVID-19, a forward selection logistic regression was performed to ascertain the effects of (1) age, (2) sex, (3) self-rated olfactory function at T0, (4) COVID-19 symptoms at T1 (fever, cough, dyspnea, chest pain, rhinorrhea, changes in food flavour, appetite loss, headache, myalgia, fatigue, diarrhea, abdominal pain, nausea), (5) chronic comorbidities with a prevalence . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 27, 2021. ; https://doi.org/10.1101/2021.12.20.21268066 doi: medRxiv preprint of more than 5% in our sample (hypertension, obesity) and (6) qualitative OD (parosmia, phantosmia, waxing and waning) at T2, on the likelihood of impairment of chemosensory function at T3. Other chronic comorbidities were not included in the model due to presence of these conditions in less than 5% of our population (heart disease, diabetes mellitus, pulmonary disease, neurological disease, cancer). Self-rated olfactory function at T1 was also excluded from the model since it violated the assumption of linearity of the log odds. were repeated at the 5-month and 11-month questionnaires and compared to determine the testretest reliability of self-evaluation (complete data set for 276 participants). To assess the intra-rater reliability of self-reported chemosensory ratings, intraclass correlation coefficients (ICC) and their 95% confidence intervals (CI) were calculated based on a mean rating (k=2), absolute agreement, two-way mixed-effects model. The ICC ranges from 0.00 (absence of reliability) to 1.00 (perfect reliability). No standard values exist for acceptable reliability using ICC, but generally, values below 0.50 indicate poor reliability, between 0.50 and 0.75 indicate moderate reliability, between 0.75 and 0.90 indicate good reliability and above 0.90 is excellent reliability 27 .

For all statistical tests, alpha type error threshold was set at 0.05. All results are expressed as mean and standard deviation (SD) unless otherwise specified.

Anonymized data not published within this article will be made available by request from any qualified investigator.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint 

Study population A total of 366 healthcare workers were included in this study. The average age was of participants was of 44.8 years old (SD: 11.7). Among them, 310 (84.7%) were women, and the majority (83.1%) were Caucasian. On average, the online questionnaire was completed 10.6 months (SD: 0.7, range: 8.9 -13.0) after the onset of COVID-19 symptoms. During the acute SARS-CoV-2 infection (T1), 307 (83.9%) and 301 (82.2%) reported lower olfactory and gustatory scores respectively compared to T0. Our study population had a higher prevalence of OD and GD than the initial survey from which our participants were recruited (OD: (χ 2 (1, N= 4908) = 52.62, P < .001); GD: (χ 2 (1, N= 4908) = 68.03, P < .001)) ( Table 1) .

Average self-evaluated olfactory sensitivity at T3 was 7.6 (2.2), compared to 9.1 (1.1) at T0; a total of 184 participants (50.3%) indicated persistent reduction of olfactory sensitivity.

Average self-evaluated gustatory sensitivity was 8.0 (2.0) at T3, compared to 9.2 (1.5) at T0; a total of 163 participants (44.5%) indicated persistent reduction of gustatory sensitivity. Average self-evaluated trigeminal sensitivity was 8.7 (1.7) at T3, compared to 9.0 (1.7) at T0; a total of 86 (23.5%) indicated persistent reduction of trigeminal sensitivity. In fact, chemosensory modality (F (2, 726) = 24.571, P < .001, ! 2 = .063; olfactory scores < gustatory scores < trigeminal scores; all P < .001) and time point (F(3, 1089) = 48.88, P < .001, ! 2 = .119; T1 scores < T2 scores < T3 scores < T0 scores, all P < .001) had an effect on self-ratings ( Figure 4 ). More specifically, the effect of time point was the strongest for olfactory ratings (F (3, 1089) = 61.677, P <.001 ! 2 = .145; T1 < T2 < T3 < T0, all P < .001), followed by gustatory ratings (Table 2) , namely (1) chest tightness at T1 (during infection), (2) dysgeusia at T1 (during infection), and (3) presence of phantosmia at T2 (5 months after infection).

Test-retest reliability of subjective chemosensory ratings Self-ratings from the first and second questionnaires correlated significantly at each of 0.320 (0.143 -0.461)) had somewhat lower test-retest reliability (Table 3) .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 27, 2021. ; https://doi.org/10.1101/2021.12.20.21268066 doi: medRxiv preprint

This study was carried out 11 months after RT-PCR-confirmed SARS-CoV-2 infection and revealed three major results. First, we found that a considerable proportion of participants still exhibited chemosensory loss of different degrees. Specifically, (a) we observed persistent reduction of olfactory (gustatory, trigeminal) sensitivity in 50% (45%, 24%) of participants; i.e., ratings had not yet returned to levels before the infection; (b) roughly a third of participants exhibited persistent olfactory and gustatory impairment; this was one out of seven for the trigeminal system; (c) roughly one quarter of participants had test scores indicative of clinically relevant OD. Second, we observed that presence of (a) chest tightness and (b) subjective dysgeusia during COVID-19 as well as (c) presence of phantosmia at 5 months were predictors for persistent olfactory impairment at 11 months. Third, we observed that the measures we used exhibited good test-retest reliability, especially for olfactory measures.

Our sample roughly exhibited 20% higher rates of reduced olfactory and sensitivity during the acute phase of COVID-19 than the initial survey respondents. Therefore, OD and GD prevalence reported from this study are probably overestimated, but it would be difficult to determine exactly how the recovery rates might differ from participating and non-participating individuals. 32% of participants exhibited persistent OD and 25% exhibited a CPT score indicating clinical OD. The prevalence of parosmia in individuals with post-COVID-19 OD has been reported to be in the range of 7% to 93% in varying degrees of severity 8, 13 . In this cohort, prevalence of parosmia was at 17% at 5 months after the infection and rose to over 50% at 11 months 20 . This is in line with a recent study that reported increasing incidence of parosmia in individuals recovering from long-haul COVID-19 17 . This finding is particularly important, as parosmia has been associated with a better olfactory outcome following olfactory training, but if unresolved, it may be a much greater source of distress than isolated hyposmia 28, 29 . Further, an important proportion . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Among all participants, olfactory function measured with a semi-objective test nominally increased between 5 months and 11 months; yet no significant difference was found in OD prevalence at 5 and 11 months using this tool. This could be interpreted as an increase in qualitative disorders combined with improved olfactory sensitivity, or lower spontaneous recovery rates for those with more severe deficits while others with milder and clinically irrelevant forms continue to recuperate.

We found that 30% of the participants in the cohort exhibited persistent GD, with bitter as the most affected taste quality. One study on taste thresholds in COVID-19 patients found that the threshold was increased for sweet, sour and bitter, but they were decreased for salty in the acute phase 31 . TD at 11 months was reported by less than 15% of participants. According to a recent study, impaired trigeminal function could play a role in local inflammatory response, which may in turn influence recovery 22 .

We explored chemosensory alterations in three different ways: A relatively high number of individuals reported at least slight alterations in chemosensitivity compared to baseline when using VAS ratings. When directly asked if a given chemical senses was a bit worse or much worse compared to baseline, a smaller number of individuals self-reported dysfunction. Therefore, even though a large proportion of individuals with post-COVID-19 chemosensory alterations might feel like their senses are not back to normal, only some of these have more severe dysfunctions. In the clinical setting, it is imperative that clinicians use the same scale or measure if they wish to followup subjective olfactory complaints as the answer may vary depending on the formulation of the question.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint Few clinical measures proved to be good indicators of olfactory prognostic following COVID-19-induced OD, in line with other reports 32, 33 . In our study, presence of (a) chest tightness and (b) taste disorders during acute COVID-19 as well as (c) presence of phantosmia at 5 months were significantly associated with a higher chance of persisting OD at 11 months. The links between these variables remain speculative. Chest tightness may indicate a more severe form of COVID-19, although OD was not associated with a more severe course of COVID-19 34 .

Participants may mistake lack of flavor perception due to reduced retronasal olfaction caused by OD as taste problems in the acute phase of COVID-19 [35] [36] [37] . This finding could either be due to more severe olfactory loss being related to longer duration of the symptom, or that GD does influence olfactory recovery by unknown mechanisms. Finally, although the pathomechanism of phantosmia is still unknown, one could expect that a more severe inflammatory reaction in the olfactory cleft may cause phantosmia and could take more time to recover 38 . One study found patients with lower levels of salivary and nasal immunoglobulins G at 60 days post-infections had better outcomes 32 . Accordingly, the presence of phantosmia increased the likelihood of OD persistence. While this suggests a role of immune local response in the evolution of persistent chemosensory disorders, further research must be conducted to accurately identify patients with a better chance of olfactory recovery. More studies will be required to validate the link between these variables, especially between qualitative OD and olfactory recovery. Meanwhile, clinicians can only continue to encourage their patients with persisting OD to try olfactory training and/or intranasal corticosteroid sprays following resolution of the infection 39-41 .

Olfactory subjective ratings had a very good test-retest reliability in our study population.

Psychophysical evaluations do remain the ideal method to measure all chemosensory disorders but the use of a 10-point VAS may have some value in monitoring OD, especially in large populations . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 27, 2021. ;  or in a social distancing setting. Previous studies have found self-ratings of olfactory function to have a poor reliability and low correlation with objective testing 42 . However, our findings suggest self-ratings could be a good alternative for clinicians with limited time or a difficult access to objective testing. These findings can be explained in the context of follow-up, especially following COVID-19, where patients are more likely to notice changes in their sense of smell through increased self-awareness of symptoms. A previous study also reported a good correlation between VAS-reported OD and the BSIT, a validated psychophysical olfactory test 26 . In our study, gustatory ratings had a moderate test-retest reliability and trigeminal had a poor test-retest reliability. This difference between chemosensory modalities was probably influenced by how well individuals understand the relation between the different sensations and each chemosensory modality. Indeed, the trigeminal system is a much less known system, and gustation is often mixed with retronasal olfaction 43, 44 . In consequence, despite providing specific definitions and examples for all three chemosensory modalities prior to rating, awareness and accuracy were lower for gustation and trigeminal sensations, possibly demonstrating the need for patient's education when presenting with chemosensory disorders.

A major limitation of this study was the absence of a commonly used psychophysical test to assess the extent of chemosensory dysfunction. Therefore, our results obtained with the CPT were more difficult to compare directly with other studies using psychophysical testing.

Unfortunately, in clinical practice, psychophysical evaluations are seldom used for the diagnosis and follow-up of chemosensory impairments, which are mostly treated based on subjective assessments. While we encourage the use of validated psychophysical tests in primary care, neurology and ENT clinics, findings in this study confirmed a reliability of questioning olfactory . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 27, 2021. ; https://doi.org /10.1101 /10. /2021 functions subjectively especially in the context of follow-up of COVID-19 patients. An additional limitation of this study was the high prevalence of chemosensory disorders during the acute phase of COVID-19. Indeed, we observed higher participation rates among individuals with chemosensory disorders than those who have either recovered or simply never noticed any OD, GD or TD. Our study sample had a 20% higher rate of OD and GD, thus probably over estimating prevalence of chemosensory disorders at 11 months.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

We thank Josiane Rivard for preparing the online questionnaire, study participants. This work was supported financially by Fonds de recherche du Québec -Santé (chercheur boursier junior 2 #283144 to JF). All authors have full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. FGL is the recipient of a tier-2 Canada research Chair. No author declares any conflict of interest.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint Comparing self-reported chemosensory scores collected at the 5-and 11-month questionnaires. T2, Q1: 5-month rating at the 5-month questionnaire; T3, Q2: 11-month rating at the 11-month questionnaire. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Raincloud plot representing self-reported scores for olfaction (A), gustation (B), and trigeminal (C) function before (T0), during (T1) and 5 (T2) and 11 (T3) months after COVID-19. Ratings from individual participants are displayed as dots. Boxplots show the first to third quartiles, horizontal line denotes the median, and whiskers denote 1.5 times interquartile range. Compared to baseline, selfreported scores of olfaction, gustation and trigeminal function were significantly lower during COVID-19 and have not fully returned to baseline values 11 months after COVID-19.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 27, 2021. ; https://doi.org/10.1101/2021.12.20.21268066 doi: medRxiv preprint

Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers

Characteristics of Olfactory Disorders in Relation to Major Causes of Olfactory Loss

Olfactory disorders following upper respiratory tract infections

Olfactory Disorders and Quality of Life-An Updated Review

Post-viral effects of COVID-19 in the olfactory system and their implications

Clinical Features in Russian Patients with COVID-Associated Parosmia/Phanthosmia. Psychiatr Danub

Phantosmia with COVID-19 Related Olfactory Dysfunction: Report of Nine Case

More Than Smell-COVID-19 Is Associated With Severe Impairment of Smell, Taste, and Chemesthesis. Chem Senses

Olfactory and gustatory dysfunctions due to the coronavirus disease (COVID-19): a review of current evidence

The Prevalence of Olfactory and Gustatory Dysfunction in COVID-19 Patients: A Systematic Review and Meta-analysis

Otolaryngol Head Neck Surg

Early recovery following new onset anosmia during the COVID-19 pandemic -an observational cohort study

Recovery From COVID-19-Related Olfactory Disorders and Quality of Life: Insights From an Observational Online Study

Six month followup of self-reported loss of smell during the COVID-19 pandemic

Prevalence and 6-month recovery of olfactory dysfunction: a multicentre study of 1363 COVID-19 patients

Six-month smell and taste recovery rates in coronavirus disease 2019 patients: a prospective psychophysical study

Patients with COVID-19-associated olfactory impairment also show impaired trigeminal function

Increasing incidence of parosmia and phantosmia in patients recovering from COVID-19 smell loss

28 -Regeneration of the Olfactory Epithelium

Stem and progenitor cells of the mammalian olfactory epithelium: Taking poietic license

Chemosensory dysfunctions induced by COVID-19 can persist up to 7 months: A study of over 700 healthcare workers

Prognosis of postviral olfactory loss: Follow-up study for longer than one year

Assessing the extent and timing of chemosensory impairments during COVID-19 pandemic

Raincloud plots: a multi-platform tool for robust data visualization

Eight-month followup of olfactory and gustatory dysfunctions in recovered COVID-19 patients. American journal of otolaryngology

Association of subjective olfactory dysfunction and 12-item odor identification testing in ambulatory COVID-19 patients

Parosmia is Associated with Relevant Olfactory Recovery After Olfactory Training. The Laryngoscope

Severe chemotherapy-induced parosmia

A study on the prognostic significance of qualitative olfactory dysfunction

Quantitative analysis of taste disorder in COVID-19 patients, the hypersensitivity to salty quality

Predictive factors of smell recovery in a clinical series of 288 coronavirus disease 2019 patients with olfactory dysfunction

Just how much of what we taste derives from the sense of smell? Flavour

Retronasal olfactory function in patients with smell loss but subjectively normal flavor perception

Taste of breath: the temporal order of taste and smell synchronized with breathing as a determinant for taste and olfactory integration

Loss of smell in patients with COVID-19

Efficacy of corticosteroid therapy in the treatment of long-lasting olfactory disorders in COVID-19 patients

Systemic corticosteroids in coronavirus disease 2019 (COVID-19)-related smell dysfunction: an international view. International forum of allergy & rhinology

Short-Term Efficacy and Safety of Oral and Nasal Corticosteroids in COVID-19 Patients with Olfactory Dysfunction: A European Multicenter Study. Pathogens

Clinical Usefulness of Self-Rated Olfactory Performance-A Data Science-Based Assessment of 6000 Patients. Chem Senses

Smell and taste disorders, a study of 750 patients from the University of Pennsylvania Smell and Taste Center

Taste and Smell